BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II
Rhea-AI Summary
BeiGene, a commercial-stage biotechnology company, announced the presentation of clinical and preclinical data at the 2020 AACR Virtual Annual Meeting II from June 22-24. The highlights include:
- Preliminary safety and efficacy data of BGB-A333 (anti-PD-L1) in advanced solid tumors.
- Data on BGB-10188 (PI3Kδ inhibitor) demonstrating improved safety and anti-tumor activities.
- Preclinical results for BGB-11417 (Bcl-2 inhibitor) showing antitumor potential in hematological models.
- RAF dimer inhibitor lifirafenib's ability to enhance MEK inhibitor activity in RAS mutant tumors.
Positive
- Presentation of promising clinical data for BGB-A333, potentially advancing its development.
- BGB-10188 reported to have improved safety profile and anti-tumor efficacy, broadening therapeutic options.
- Preclinical data for BGB-11417 demonstrates strong anti-tumor activity, indicating strong pipeline potential.
- Lifirafenib shows increased efficacy when used with MEK inhibitor, suggesting innovative combination therapies.
Negative
- None.
News Market Reaction – BGNE
On the day this news was published, BGNE gained 1.85%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that clinical data on its investigational anti-PD-L1 antibody BGB-A333 and preclinical data on three early-stage drug candidates will be presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II, taking place on June 22-24, 2020.
Poster Presentations:
| Title: | Preliminary safety and efficacy data of BGB-A333, an anti-PD-L1 monoclonal antibody, alone and in combination with tislelizumab in patients with advanced solid tumors |
| Abstract #: | 9496 |
| Poster Board #: | CT253 |
| Session Category: | CT01 Phase 1 Adult Clinical Trial |
| Session Title: | Phase 1 Trials in Progress |
| Lead Author: | Jayesh Desai, MBBS, FRACP, Peter MacCallum Center Centre, Australia |
| Title: | BGB-10188, a highly selective PI3Kδ inhibitor with improved safety profile and superior anti-tumor activities in vivo |
| Abstract #: | 664 |
| Poster Board #: | 11 |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | PI3K/AKT/mTOR Inhibitors |
| Lead Author: | Xiao Yang, BeiGene |
| Title: | Preclinical characterization of BGB-11417, a potent and selective Bcl-2 inhibitor with superior antitumor activities in haematological tumor models |
| Abstract #: | 3077 |
| Poster Board #: | 11 |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Topoisomerases, Tubulin, and Other Small Molecule Therapeutic Agents |
| Lead Author: | Nan Hu, BeiGene |
| Title: | RAF dimer inhibitor lifirafenib enhances the antitumor activity of MEK inhibitor mirdametinib in RAS mutant tumors |
| Abstract #: | 6415 |
| Poster Board #: | 9 |
| Session Category: | Experimental and Molecular Therapeutics |
| Session Title: | Novel Therapeutic Approaches |
| Lead Author: | Xi Yuan, BeiGene |
About BeiGene
BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Our 3,800+ employees in China, the United States, Australia, and Europe are committed to expediting the development of a diverse pipeline of novel therapeutics for cancer. We currently market two internally-discovered oncology products: BTK inhibitor BRUKINSA™ (zanubrutinib) in the United States, and anti-PD-1 antibody tislelizumab in China. We also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics Sàrl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma. To learn more about BeiGene, please visit www.beigene.com and follow us on Twitter at @BeiGeneUSA.
| BeiGene Investor Contact | BeiGene Media Contact | |
| Craig West +1 857-302-5189 ir@beigene.com | Liza Heapes +1 857-302-5663 media@beigene.com |
FAQ
What are the key findings for BGB-A333 presented by BeiGene at the AACR 2020?
When will BeiGene present data at the AACR Annual Meeting?
What is the significance of BGB-10188's data presented at the AACR 2020?
What is the potential market impact of BeiGene's new data presented?
What does the data on lifirafenib indicate?
